I am of the opinion that Omnicar and cellpryme have been well...

I am of the opinion that Omnicar and cellpryme have been well and truly factored out of the current Market cap of PTX. 35M for a company heading into a phase 2 trial with orphan drug designation and the very real possibility of a registration trial.

Typically, leading upto the potential of such a huge catalyst, you would expect the SP to show signs of “buy the rumour, sell the fact”. However the constant sell off says to me that there is an arm wrestle between those exiting due to omnicar being put on ice and those buying in for PTX-100.

We need Steven to pull a rabbit out of his hat in regards to Omnicar/cellpryme to see the SP break its current trend IMO! As ainsleym suggested, I would at this stage be happy to see a JV to get omnicar into the clinic. It would reduce the cost of the trials and will showcase to the world exactly what it can do.